Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0050
+0.0010 (25.00%)
Sep 25, 2026, 4:10 PM AEST
Chimeric Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | - | 3.97 | - | - | - |
Other Revenue | -0.19 | 8.72 | 7.46 | 4.51 | 2.62 |
| -0.19 | 12.68 | 7.46 | 4.51 | 2.62 | |
Revenue Growth | - | 70.09% | 65.52% | 72.16% | - |
Cost of Revenue | - | 0.85 | - | - | - |
Gross Profit | -0.19 | 11.84 | 7.46 | 4.51 | 2.62 |
Selling, General & Admin | 4.6 | 6.45 | 9 | 11.73 | 7.9 |
Research & Development | 3.42 | 10.79 | 10.19 | 14.43 | 6.12 |
Operating Expenses | 8.36 | 18.33 | 19.76 | 29.49 | 17.19 |
Operating Income | -8.55 | -6.49 | -12.31 | -24.98 | -14.57 |
Interest Expense | -0.29 | -0.21 | -0.01 | -0.77 | -0.64 |
Interest & Investment Income | 0.04 | 0.05 | 0.12 | 0.03 | 0.01 |
Currency Exchange Gain (Loss) | 0.3 | -0.11 | 0.06 | -0.09 | -0.53 |
Other Non Operating Income (Expenses) | -0.02 | -0 | 0.58 | - | - |
EBT Excluding Unusual Items | -8.51 | -6.77 | -11.56 | -25.82 | -15.73 |
Gain (Loss) on Sale of Assets | - | -0 | -0 | -0 | -0 |
Asset Writedown | -10.27 | - | - | - | - |
Other Unusual Items | - | -3.55 | -0.96 | - | - |
Pretax Income | -18.79 | -10.32 | -12.52 | -25.82 | -15.73 |
Income Tax Expense | 0.02 | 0.11 | 0.01 | 0.09 | 0.16 |
Net Income | -18.81 | -10.43 | -12.53 | -25.92 | -15.9 |
Net Income to Common | -18.81 | -10.43 | -12.53 | -25.92 | -15.9 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 31 | 14 | 7 | 4 | 4 |
Shares Outstanding (Diluted) | 31 | 14 | 7 | 4 | 4 |
Shares Change | 128.20% | 94.34% | 60.57% | 20.37% | 97.88% |
EPS (Basic) | -0.61 | -0.77 | -1.80 | -5.98 | -4.42 |
EPS (Diluted) | -0.61 | -0.77 | -1.80 | -5.98 | -4.42 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -10.78 | -7.28 | -7.54 | -16.31 | -13.17 |
Free Cash Flow Per Share | -0.35 | -0.54 | -1.08 | -3.76 | -3.66 |
Gross Margin | - | 93.32% | 100.00% | 100.00% | 100.00% |
Operating Margin | - | -51.14% | -165.01% | -554.44% | -556.82% |
Profit Margin | - | -82.23% | -168.01% | -575.20% | -607.48% |
Free Cash Flow Margin | - | -57.36% | -101.07% | -361.89% | -503.04% |
EBITDA | -8.03 | -5.46 | -11.22 | -24.02 | -13.62 |
EBITDA Margin | - | -43.01% | -150.50% | - | - |
D&A For EBITDA | 0.52 | 1.03 | 1.08 | 0.97 | 0.95 |
EBIT | -8.55 | -6.49 | -12.31 | -24.98 | -14.57 |
EBIT Margin | - | -51.14% | -165.01% | - | - |